Spectrum Pharmaceuticals, Inc.

Total net sales for Q4 2022 and full-year 2022 were $10.1 million, all from the first commercial quarter of ROLVEDON. Cost of sales was $1.8 million in the quarter and year, including packaging, freight, royalties, and $1.1 million of start-up testing costs. SG&A was $11.3 million in Q4 and $38.8 million for the year, versus $18.9 million and $16.4 million in the comparable 2021 periods; R&D was $8.7 million in Q4 and $42.2 million for the year, versus $18 million and $87.3 million in 2021. Net loss from continuing operations was $11.7 million, or $0.06 per share, in Q4 2022 versus $39.8 million, or $0.26 per share, in Q4 2021; for the full year it was $78.1 million, or $0.43 per share, versus $158.4 million, or $1.02 per share. Operating cash burn was approximately $97 million in 2022 versus $119.5 million in 2021. The company ended Q4 with approximately $75.1 million in cash, cash equivalents and marketable securities and said it believes it has enough resources, including potential SLR draws, to fund operations through 2024. Management did not provide formal revenue or EPS guidance for next quarter or full year, saying it wanted a few quarters of launch experience before giving guidance.

Tom Riga framed 2022 as a transition year from development-stage to commercial-stage operations, with ROLVEDON now the main strategic focus. He emphasized disciplined cost cutting and said the company is “well positioned” to keep investing in the launch while maintaining a lean operating structure. His tone was upbeat but cautious: he highlighted early launch receptivity, NCCN inclusion, and the new J-Code, while repeatedly noting that ROLVEDON’s success must be sustained over time.

Nora Brennan focused on the sharp reset in the cost structure and the company’s liquidity. She detailed Q4 and full-year spending, including $11.3 million of SG&A in Q4, $38.8 million for the year, and $8.7 million of R&D in Q4 and $42.2 million for the year; she also noted the lower 2022 cash burn of about $97 million. Brennan said the quarter ended with approximately $75.1 million in cash, cash equivalents and marketable securities, plus access to up to $25 million more from SLR Capital Partners tied to revenue milestones, and said those resources should fund operations through 2024.

Analysts focused heavily on the new J-Code, pricing/reimbursement predictability, payer coverage, launch trajectory by segment, and whether the strong Q4 account growth could be translated into revenue growth. Management said the J-Code mainly removes reimbursement friction and shortens payment cycle time, but declined to give guidance yet, saying they want several quarters under their belt first. On access, Erin Miller said the company has engaged 100% of target payers representing 73% of total insured lives and has three payer agreements in place; on the hospital segment, management said uptake is being slowed by timing, P&T committee processes, and in some cases the fact that ROLVEDON will not always be the least-cost option.